Gufic Biosciences Limited: Acquisition
Gufic Biosciences, a BSE/NSE-listed pharmaceutical company, notified the exchange of an acquisition on 14 August 2026. The NSE archive filing provides formal notice but no detailed terms, consideration, target name, or completion date are visible in the headline extract. The full acquisition structure, regulatory approvals (DCGI, FIPB/DPIIT if applicable, CCI if turnover thresholds crossed) and closing conditions will require review of the complete disclosure document.
Why it mattersPharma M&A in India requires pre-closing DCGI/CDSCO approval if the target holds manufacturing or regulatory licenses; counsel must sequence approvals with stock exchange disclosure timing and foreign-exchange compliance if cross-border.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Filings Archive · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026